将PD-L1表达水平、既往是否接受过以治愈为目的治疗以及ECOG评分作为分层因素。 基线显示,两组均有~89%的患者PD-L1≥1%(TAP score),~43%的患者PD-L1≥10%。 主要终点OS方面,截至2023年2月13日,最短生存随访时间14.5个月,Tiragolumab+阿替利珠单抗组和安慰剂组的中位OS分别为15.7个月和11.1个月(HR=0.70,95...
A higher ESCC score was associated with better mobility. We also found that the SINS score recommended guidance correlated with management of surgical patients who presented with MSCC within the tertiary centre.doi:10.1093/bjs/znac039.086R. Peris...
[19] developed a CT-based radiomics model to predict the PNI in rectal cancer, achieving an AUC of 0.82, which improved to 0.88 by combining the radiomics score with CT-derived T and N categories in the training set. Guo et al. [21] found that among the single-modality models, the ...
Methods:方法 The ESCC patients who received neoadjuvant CF or DCF at 85 Japanese esophageal centers certified by Japan Esophageal Society were retrospectively reviewed. After propensity score (PS) matching, the overall survival (OS) and recurrence free survival (RFS) were compared bet ween CF and D...
Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A). Transl Cancer Res. 2021;10(6):2932–43. https://doi.org/10.21037/tcr-21-505....
Here, they looked at the [tumor proportion score] TPS and the cut off was 1 or higher as positive and less than 1 as negative. So, it was not 10. Approximately 55% of patients had a TPS of at least 1. It will be easier to select patients [for these regimens], although th...
(none), 1 (<20%), 2 (20–50%), 3 (51–75%), and 4 (>75%). Cutoff values for low and high expression groups were determined by using the degree × intensity staining rank. Low expression was defined as a final score < 6 and high expression was defined as a final score ≥ 6...
The study’s primary end point was OS in the ITT patient population. Key secondary end points included investigator-assessed progression-free survival (PFS), overall response rate, duration of response, OS in patients with a PD-L1 tumor area positivity score of 10% or greater, and safety....
Key secondary end points included investigator-assessed progression-free survival (PFS), overall response rate, duration of response, OS in patients with a PD-L1 tumor area positivity score of 10% or greater, and safety. Notably, tumor response was assessed per RECIST 1.1 criteria every...
TIS (an anti–PD-1 antibody) + CT demonstrated significant overall survival (OS) benefit vs PBO + CT as first-line (1L) therapy for advanced ESCC in all randomized patients (pts; stratified HR 0.66) and pts with PD-L1 Tumor Area Positivity (TAP) score ≥10% (stratified HR 0.62) (RAT...